Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:BRNS NASDAQ:ENVB NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.02$1.23$0.88▼$5.48$25.95M0.4277,860 shs982 shsBRNSBarinthus Biotherapeutics$0.69+2.2%$0.61$0.51▼$2.92$27.94M-0.4338,862 shs712 shsENVBEnveric Biosciences$2.75-2.1%$2.54$1.71▼$17.84$5.50M1.242.87 million shs13,914 shsMRKRMarker Therapeutics$1.46+0.8%$1.44$0.81▼$4.07$24.42M1.43240,797 shs2,054 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-3.77%-0.97%-28.67%-40.00%-15.70%BRNSBarinthus Biotherapeutics+5.82%+8.96%+24.93%-0.14%-18.22%ENVBEnveric Biosciences-1.40%-29.57%+43.37%+30.70%-81.71%MRKRMarker Therapeutics-0.68%-0.68%-17.14%-6.45%+25.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.02$1.23$0.88▼$5.48$25.95M0.4277,860 shs982 shsBRNSBarinthus Biotherapeutics$0.69+2.2%$0.61$0.51▼$2.92$27.94M-0.4338,862 shs712 shsENVBEnveric Biosciences$2.75-2.1%$2.54$1.71▼$17.84$5.50M1.242.87 million shs13,914 shsMRKRMarker Therapeutics$1.46+0.8%$1.44$0.81▼$4.07$24.42M1.43240,797 shs2,054 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-3.77%-0.97%-28.67%-40.00%-15.70%BRNSBarinthus Biotherapeutics+5.82%+8.96%+24.93%-0.14%-18.22%ENVBEnveric Biosciences-1.40%-29.57%+43.37%+30.70%-81.71%MRKRMarker Therapeutics-0.68%-0.68%-17.14%-6.45%+25.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/ABRNSBarinthus Biotherapeutics 2.00Hold$4.00483.94% UpsideENVBEnveric Biosciences 1.00SellN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00584.46% UpsideCurrent Analyst Ratings BreakdownLatest ENVB, ABVC, MRKR, and BRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K50.88N/AN/A$0.52 per share1.96BRNSBarinthus BiotherapeuticsN/AN/AN/AN/A$1.82 per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$7.00 per shareN/AMRKRMarker Therapeutics$3.55M6.86N/AN/A$1.01 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-65.11%-40.13%5/19/2026 (Estimated)BRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%N/AENVBEnveric Biosciences-$8.77M-$37.11N/AN/AN/AN/A-255.43%-193.77%5/19/2026 (Estimated)MRKRMarker Therapeutics-$12.16M-$0.85N/AN/AN/A-343.03%-80.86%-67.04%5/21/2026 (Estimated)Latest ENVB, ABVC, MRKR, and BRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026MRKRMarker Therapeutics-$0.18N/AN/AN/A$0.68 millionN/A4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/A3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 million3/13/2026Q4 2025BRNSBarinthus Biotherapeutics-$0.40-$0.27+$0.13-$0.27N/AN/A3/3/2026Q4 2025ABVCABVC BioPharmaN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.410.41BRNSBarinthus BiotherapeuticsN/A6.056.05ENVBEnveric BiosciencesN/A5.385.38MRKRMarker TherapeuticsN/A8.398.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%BRNSBarinthus Biotherapeutics25.20%ENVBEnveric Biosciences13.82%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%BRNSBarinthus Biotherapeutics10.70%ENVBEnveric Biosciences2.41%MRKRMarker Therapeutics5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3025.44 million20.61 millionNot OptionableBRNSBarinthus Biotherapeutics10740.85 million37.58 millionN/AENVBEnveric Biosciences201.99 million1.94 millionNot OptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableENVB, ABVC, MRKR, and BRNS HeadlinesRecent News About These CompaniesMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comMARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesMarch 18, 2026 | zacks.comMarker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-OncologyMarch 18, 2026 | quiverquant.comQMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsMarch 18, 2026 | globenewswire.comMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell TechnologyJanuary 26, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)January 22, 2026 | theglobeandmail.comMRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowJanuary 21, 2026 | zacks.comMarker Therapeutics, Inc. Common Stock (MRKR)January 9, 2026 | nasdaq.comMARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?January 7, 2026 | zacks.com5 Small Drug Stocks to Buy as Industry Recovery Picks UpJanuary 7, 2026 | zacks.comMarker Therapeutics announces publication on MAR-T cells in pancreatic cancerJanuary 5, 2026 | msn.comBaylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerJanuary 5, 2026 | globenewswire.comHere's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash WiselyDecember 18, 2025 | finance.yahoo.comHC Wainwright & Co. initiates coverage of Marker Therapeutics (MRKR) with buy recommendationDecember 8, 2025 | msn.comMarker Therapeutics initiated with a buy at HC WainwrightDecember 8, 2025 | msn.comMarker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 14, 2025 | globenewswire.comMarker Therapeutics appoints Penkus Corzo to board of directorsNovember 5, 2025 | msn.comMarker Therapeutics appoints Kathryn Penkus Corzo to Board of DirectorsNovember 5, 2025 | globenewswire.comCanaccord Genuity Keeps Their Buy Rating on Marker Therapeutics (MRKR)November 4, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, ABVC, MRKR, and BRNS Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.02 0.00 (0.00%) As of 09:51 AM Eastern This is a fair market value price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Barinthus Biotherapeutics NASDAQ:BRNS$0.68 +0.02 (+2.24%) As of 09:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Enveric Biosciences NASDAQ:ENVB$2.75 -0.06 (-2.06%) As of 09:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Marker Therapeutics NASDAQ:MRKR$1.46 +0.01 (+0.76%) As of 09:51 AM Eastern This is a fair market value price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
